Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Tag: radiotherapy
Uterine Leiomyosarcoma: A Meta-Analysis Of Systemic Therapy Effectiveness
Uterine Leiomyosarcoma: Systemic Therapy Effectiveness Overview Uterine leiomyosarcoma (uLMS) is an aggressive type of mesenchymal tumor linked to a bleak prognosis. The primary treatment for advanced uLMS is systemic chemotherapy, although the most effective regimen remains uncertain. To address this, we conducted an extensive analysis, including both meta-analysis and metaregression, aiming to
Radiation therapy And VTE Risk
Radiation therapy And VTE Risk Thromboembolic events are often the primary cause of complications in malignancies. They also have a major effect on the morbidity and mortality of cancer patients. Compared to chemotherapy and other kinds of systemic therapies, there’s not enough data about the impact of ionizing radiation on the
Pseudouveitis with pancreatic carcinoma: a case study
Pseudouveitis with pancreatic carcinoma: a case study Overview of the Study This study is a report of a case of a 61- year- old man who presented with progressive deterioration of general condition with unilateral recurrent episodes of pseudouveitis presenting as non- granulomatous panuveitis of the left eye related to a choroidal
Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence
Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence STUDY BACKGROUND Sinonasal lymphoma is a rare malignancy of rhinologic origin affecting the sinonasal region and surrounding structures. It is a type of non-Hodgkin lymphoma (NHL) comprising around 1.5% of all lymphomas and usually involves males aged between 40 and 70 years.
